Search Results

TriLink BioTechnologies, a Maravai™ LifeSciences company and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery.

Danaher Corporation, a global science and technology innovator, launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild TBI.

Inhibitor Therapeutics, Inc. has entered into an exclusive, worldwide licensing agreement with Johns Hopkins University for their U.S Patent 8,980,930 “New Angiogenesis Inhibitors”.

Unravel Biosciences, Inc., (“Unravel”), an AI-enabled therapeutics company established to advance drugs for complex diseases, and the Pitt Hopkins Research Foundation (the “Foundation”) today announced a collaboration to conduct a proof of concept clinical trial of vorinostat (RVL-001) in patients with Pitt Hopkins Syndrome (PTHS).

Exagen Inc., a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced the execution of an exclusive license agreement.

Allosteric Bioscience, Inc. (ABI) has signed a Sponsored Research Agreement (SRA) with Dr. Susan Michaelis at Johns Hopkins University for analysis of chemical leads for modulation (increase or decrease) of key protein targets for Optimizing Aging and Longevity.

Cybrexa Therapeutics today announced that John Maraganore, Ph.D., has joined as a Strategic Advisor to the Company’s Executive Leadership Team.

Neuren Pharmaceuticals announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome.